NM81
Inflammatory Bowel Disease (IBD)
Key Facts
About Numab Innovation
Numab Therapeutics is a Zurich-based biotech pioneering a rational, platform-based approach to design multispecific antibodies with tailored pharmacokinetics. The company's core value proposition lies in its proprietary λ-Cap™ and MATCH™ technologies, which enable the reproducible creation of novel therapeutics intended to overcome limitations of first-generation antibodies. It is advancing a proprietary pipeline led by NM26 for atopic dermatitis while simultaneously validating its platform through multiple high-value collaborations with partners like Boehringer Ingelheim and Kaken Pharmaceutical. The recent appointment of a seasoned CEO with significant commercial and deal-making experience signals a maturation phase focused on pipeline advancement and strategic partnerships.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease (IBD) Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM2001 | Harbour BioMed | Discovery |
| Metabolite Delivery Platform (Therapeutic Programs) | ClostraBio | Pre-clinical |
| ABO21009 | AboleIIs Pharma | Phase 1 |
| GlyHealth Biomarkers | Avenna | Pre-clinical/Validation |
| GTI-850 | GSNO Therapeutics | Pre-clinical |
| CK-0045 | Cytoki Pharma | Pre-clinical/Research |
| MV-010 | MV BioTherapeutics | Preclinical |
| LIAISON® Calprotectin | DiaSorin | Commercial |
| SL-325 | Shattuck Labs | Phase 2 |
| SL-425 | Shattuck Labs | Phase 1 |
| VE202 | PureTech Health | Phase 2 |